Glucagon-like peptide-1 receptor blockade impairs islet secretion and glucose metabolism in humans
Journal of Clinical Investigation · 2023
DOI: 10.1172/jci173495 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2023. Verfasst von Andrew A Welch und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes & Metabolism, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hyperglycemia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NIDDK NIH HHS, NIH / NIDDK.
Abstract (Originalsprache)
BACKGROUNDProglucagon can be processed to glucagon-like peptide1 (GLP-1) within the islet, but its contribution to islet function in humans remains unknown. We sought to understand whether pancreatic GLP-1 alters islet function in humans and whether this is affected by type 2 diabetes.METHODSWe therefore studied individuals with and without type 2 diabetes on two occasions in random order. On one occasion, exendin 9-39, a competitive antagonist of the GLP-1 Receptor (GLP1R), was infused, while on the other, saline was infused. The tracer dilution technique ([3-3H] glucose) was used to measure glucose turnover during fasting and during a hyperglycemic clamp.RESULTSExendin 9-39 increased fasting glucose concentrations; fasting islet hormone concentrations were unchanged, but inappropriate for the higher fasting glucose observed. In people with type 2 diabetes, fasting glucagon concentrations were markedly elevated and persisted despite hyperglycemia. This impaired suppression of endogenous glucose production by hyperglycemia.CONCLUSIONThese data show that GLP1R blockade impairs islet function, implying that intra-islet GLP1R activation alters islet responses to glucose and does so to a greater degree in people with type 2 diabetes.TRIAL REGISTRATIONThis study was registered at ClinicalTrials.gov NCT04466618.FUNDINGThe study was primarily funded by NIH NIDDK DK126206. AV is supported by DK78646, DK116231 and DK126206. CDM was supported by MIUR (Italian Minister for Education) under the initiative "Departments of Excellence" (Law 232/2016).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes & Metabolism, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
- Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Women and Children's Health and.
- Department of Information Engineering, University of Padova, Padova, Italy.
- Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA.
Förderung
- NCATS NIH HHS
- NIDDK NIH HHS
- NIH / NIDDK
Zitieren
APA
Welch, A. A., Farahani, R. A., Egan, A. M., Laurenti, M. C., Zeini, M., Vella, M., Bailey, K. R., Cobelli, C., Dalla Man, C., Matveyenko, A., & Vella, A. (2023). Glucagon-like peptide-1 receptor blockade impairs islet secretion and glucose metabolism in humans. Journal of Clinical Investigation. https://doi.org/10.1172/jci173495
Vancouver
Welch AA, Farahani RA, Egan AM, Laurenti MC, Zeini M, Vella M, et al. Glucagon-like peptide-1 receptor blockade impairs islet secretion and glucose metabolism in humans. Journal of Clinical Investigation. 2023. doi:10.1172/jci173495
BibTeX
@article{Welch2023,
author = {Welch, Andrew A and Farahani, Rahele A and Egan, Aoife M and Laurenti, Marcello C and Zeini, Maya and Vella, Max and Bailey, Kent R and Cobelli, Claudio and Dalla Man, Chiara and Matveyenko, Aleksey and Vella, Adrian},
title = {Glucagon-like peptide-1 receptor blockade impairs islet secretion and glucose metabolism in humans},
journal = {Journal of Clinical Investigation},
year = {2023},
doi = {10.1172/jci173495}
}
EUVIMED